The first generation drug Exenatide's patent was filed in 1992, but got approved in 2005. The latest one is Tirzepatide, a dual agonist, approved in 2022. Expect soon for Retaglutide, a triple agnonist, in the market.

Not the newer ones that have lower risks of lifetime digestive issues.